Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
BTMD 
biote Corp (BTMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: BTMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.21
1 Year Target Price $4.21
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.28% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 121.06M USD | Price to earnings Ratio 3.2 | 1Y Target Price 4.21 |
Price to earnings Ratio 3.2 | 1Y Target Price 4.21 | ||
Volume (30-day avg) 6 | Beta 1.16 | 52 Weeks Range 2.31 - 6.03 | Updated Date 01/9/2026 |
52 Weeks Range 2.31 - 6.03 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.72% | Operating Margin (TTM) 18.12% |
Management Effectiveness
Return on Assets (TTM) 21.95% | Return on Equity (TTM) - |
Valuation
Trailing PE 3.2 | Forward PE 6.28 | Enterprise Value 153526352 | Price to Sales(TTM) 0.62 |
Enterprise Value 153526352 | Price to Sales(TTM) 0.62 | ||
Enterprise Value to Revenue 0.78 | Enterprise Value to EBITDA 3.31 | Shares Outstanding 30680960 | Shares Floating 21390439 |
Shares Outstanding 30680960 | Shares Floating 21390439 | ||
Percent Insiders 13.35 | Percent Institutions 63.09 |
Upturn AI SWOT
biote Corp
Company Overview
History and Background
biote Corp. was founded in 2013 with a mission to optimize hormone and nutrient levels for individuals seeking improved health and well-being. The company has rapidly grown its network of affiliated clinics and practitioners across the United States, establishing itself as a leader in the field of bioidentical hormone replacement therapy (BHRT) and nutritional optimization.
Core Business Areas
- Hormone Optimization Therapy: biote provides bioidentical hormone pellets for men and women to address common symptoms associated with hormonal imbalances, such as fatigue, mood swings, and decreased libido.
- Nutritional Optimization: The company offers a range of custom-compounded nutritional supplements designed to support overall health, energy levels, and well-being, often tailored to individual patient needs identified through lab testing.
- Practitioner Training and Support: biote offers comprehensive training and ongoing support to healthcare practitioners looking to incorporate its proprietary protocols and products into their practices.
Leadership and Structure
biote Corp. is led by a management team with expertise in healthcare, business development, and operations. The company operates through a network of affiliated medical practices and independent practitioners who utilize biote's proprietary systems and products.
Top Products and Market Share
Key Offerings
- Bioidentical Hormone Pellets: biote's signature product, offering custom-compounded BHRT pellets for men and women. While specific market share data for this niche segment is not publicly disclosed, biote is a recognized leader. Competitors include other BHRT providers, compounding pharmacies, and traditional hormone therapy options.
- Custom-Compounded Nutritional Supplements: A range of proprietary supplements designed to complement hormone therapy and address specific nutrient deficiencies. Market share data is not granularly available, with competitors including general supplement manufacturers and other specialized nutritional companies.
Market Dynamics
Industry Overview
The hormone optimization and personalized nutrition market is experiencing significant growth, driven by increasing awareness of the impact of hormones and nutrients on overall health, aging populations, and a growing demand for personalized wellness solutions. The BHRT segment, in particular, is seeing rising adoption.
Positioning
biote is positioned as a leading provider of bioidentical hormone replacement therapy and integrated nutritional optimization solutions through its extensive network of affiliated practitioners. Its key competitive advantages include its proprietary pelleting system, comprehensive training programs for healthcare providers, and a strong brand recognition within the BHRT community.
Total Addressable Market (TAM)
The TAM for hormone optimization and personalized wellness is substantial and growing. While specific figures for biote's direct market are difficult to isolate, the global wellness market is valued in the trillions. biote addresses a significant portion of the BHRT and personalized supplement market through its practitioner-focused model.
Upturn SWOT Analysis
Strengths
- Established brand recognition in the BHRT market.
- Extensive network of affiliated practitioners and clinics.
- Proprietary pelleting technology for hormone delivery.
- Comprehensive training and support for healthcare providers.
- Focus on personalized treatment plans.
Weaknesses
- Reliance on a network of independent practitioners, which can lead to variability in service delivery.
- Limited direct-to-consumer marketing, primarily operating through healthcare providers.
- Potential for increasing competition from other BHRT and wellness providers.
- The need for ongoing regulatory compliance in the healthcare sector.
Opportunities
- Expansion into new geographic markets.
- Development of new product lines in related wellness areas.
- Increased adoption of telehealth and remote patient monitoring.
- Partnerships with larger healthcare systems or insurance providers.
- Growing consumer interest in preventative health and longevity.
Threats
- Changes in regulatory landscape for BHRT and compounded medications.
- Intensifying competition from both established and emerging players.
- Negative publicity or public perception regarding hormone therapy.
- Economic downturns impacting consumer discretionary spending on wellness.
- Advancements in alternative therapies that may offer similar benefits.
Competitors and Market Share
Key Competitors
- Compounding Pharmacies (various)
- Other BHRT Providers (e.g., Everlywell, HealthGAINS)
- Integrated Wellness Clinics
Competitive Landscape
biote's competitive advantage lies in its integrated model, offering both the hormone pellets and the training/support for practitioners. However, it faces competition from specialized compounding pharmacies and a growing number of direct-to-consumer wellness and BHRT services.
Growth Trajectory and Initiatives
Historical Growth: biote Corp. has demonstrated significant historical growth since its inception, driven by the expansion of its practitioner network and increasing demand for its BHRT and nutritional optimization services.
Future Projections: Future growth projections are not publicly available. However, the company is well-positioned to capitalize on the growing wellness and hormone optimization markets.
Recent Initiatives: Recent initiatives likely focus on expanding its practitioner network, enhancing its product offerings, and potentially exploring new delivery models for its services.
Summary
biote Corp. is a significant player in the growing bioidentical hormone replacement therapy and personalized nutrition market. Its strengths lie in its established practitioner network and proprietary delivery system. However, its reliance on independent providers and the increasing competitive landscape present challenges. Continued innovation and strategic expansion will be key to its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website (biote.com)
- Industry reports on the wellness and BHRT markets
- Financial news outlets (for general industry trends and competitor information)
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. biote Corp. is a privately held company, and detailed financial data is not publicly disclosed. Market share percentages are estimates based on industry trends and competitive landscapes. This information is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About biote Corp
Exchange NASDAQ | Headquaters Irving, TX, United States | ||
IPO Launch date 2021-04-28 | CEO & Director Mr. Bret Christensen | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 217 | Website https://www.biote.com |
Full time employees 217 | Website https://www.biote.com | ||
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.